Bill Will Allow Doctors to Negotiate Jointly With HMOs

Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against

The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against antitrust law. But H.R. 1304, which passed by a vote of 26-2, would provide an exemption that has been sought by nearly every medical provider group, including the AMA, in Washington. Sponsored by Rep. Tom Campbell (R-CA), the bill is opposed by the managed care industry and the Clinton administration, both of which claim that it will enable physicians to greatly increase their fees. “Antitrust exemptions are intended to augment providers’ incomes,” argues Chip Kahn, president of the Health Insurance Association of America (HIAA). But Donald J. Palmisano, MD, an AMA trustee, argues that managed care plans have too much market power over physicians. “The role of physician as patient advocate can be easily undermined when a physician has no leverage in the face of a large, controlling health plan,” states Palmisano. Nearly a majority of House members are cosponsors of H.R. 1304, the House should pass it. Prospects for Senate approval are good, too.

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content